Hip osteoarthritis (OA) develops when protective cartilage lining the femoral head and acetabulum undergoes progressive degradation—triggered by mechanical wear, inflammation, prior injury, or metabolic dysfunction—exposing the underlying bone.
Hip osteoarthritis (OA) develops when protective cartilage lining the femoral head and acetabulum undergoes progressive degradation—triggered by mechanical wear, inflammation, prior injury, or metabolic dysfunction—exposing the underlying bone. Cartilage lesions enlarge, bone spurs form, and synovial fluid (joint lubricant) becomes inflamed. Pain, stiffness, and loss of range of motion ensue, eventually limiting walking and activities of daily living. Cell therapy in hip OA leverages placental MSCs, engineered chondrocytes, and exosomes to deliver anti-inflammatory and cartilage-regenerative signals directly into the joint. Intra-articular injection (into the joint space) positions cells to interact with damaged cartilage surfaces, synovial tissue, and local immune cells, potentially slowing degeneration or promoting cartilage matrix repair.
| Индикативна цена · България (ЕС) | €3,000–€8,000 |
|---|---|
| Глобален диапазон на пазарната цена | €4,600–€9,200 (dvcstem.com) |
| Основни видове клетки, които се изучават | MSCs from Amniotic Membrane, Chondrocytes, Exosomes |
| Статус на одобрение | Експериментален |
| Регистрирани проучвания (ClinicalTrials.gov) | 12 · 3 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Twelve completed trials and 3 actively recruiting trials are registered for hip osteoarthritis cell therapy, predominantly using placental MSC or chondrocyte injection into the hip joint under fluoroscopic guidance. Trial cohorts span mild-to-moderate radiographic OA (Kellgren-Lawrence grades 2–3) and include both primary OA and post-traumatic arthritis. Cartilage imaging by MRI has shown improved signal intensity (suggesting rehydrated cartilage matrix) in 40–60% of treated hips at 12 months. Pain scores and functional metrics (6-minute walk distance, Harris Hip Score) improve modestly in 55–75% of participants over 6–24 months, though comparative data versus placebo injection are sparse.
Depending on assessment, a Hip Osteoarthritis protocol may draw on:
Hip intra-articular cell injection costs €3,500–6,000 per treatment session, reflecting fluoroscopic guidance, joint-space access, cell preparation, and sterile protocols. Imaging—baseline and follow-up MRI or CT—adds €1,200–2,000. Many participants undergo two to three injections spaced 8–12 weeks apart to achieve optimal effect, bringing total cost to €10,000–18,000 or more. Physiotherapy guidance post-injection is advisable, adding further expense.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Hip Osteoarthritis cost-by-country breakdown, or compare the best countries for Hip Osteoarthritis →
Before booking, check safety & regulation, the recovery climate, дали бихте могли да бъдете кандидат, and which cell type fits Hip Osteoarthritis.
Пълен Артроза на тазобедрото ЧЗВ → · Разбор на разходите Артроза на тазобедрото →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Съм ли кандидат? · Какъв тип клетки? · Types of clinics & best countries · Калкулатор на разходи
Медицински преглед от редакционния екип на StemCellAtlas с Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка